The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis
Open accessPublished version of a preprint
Abstract
BACKGROUND There is disagreement about the level of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We conducted a living systematic review and meta-analysis to address three questions: 1. amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? 2. Amongst people with SARS-CoV-2 infection who are asymptomatic when diagnosed, what proportion will develop symptoms later? 3. What proportion of SARS-CoV-2 transmission is accounted for by people who are either asymptomatic throughout infection, or pre-symptomatic? METHODS AND FINDINGS We searched PubMed, Embase, bioRxiv and medRxiv using a database of SARS-CoV-2 literature that is updated daily, on 25 March 2020, 20 April 2020 and 10 June 2020. Studies of people with SARS-CoV-2 diagnosed by reverse transcriptase PCR that documented follow-up and symptom status at the beginning and end of follow-up, or modelling studies were included. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with an adapted checklist for case series and the relevance and credibility of modelling studies were assessed using a published checklist. We included a total of 94 studies. The overall estimate of the proportion of people who become infected with SARS-CoV-2 and remain asymptomatic throughout infection was 20% (95% CI 17-25) with a prediction interval of 3-67% in 79 studies that addressed this review question. There was some evidence that biases in the selection of participants influence the estimate. In seven studies of defined populations screened for SARS-CoV-2 and then followed, 31% (95% CI 26-37%, prediction interval 24-38%) remained asymptomatic. The proportion of people that is pre-symptomatic could not be summarised, owing to heterogeneity. The secondary attack rate was slightly lower in contacts of people with asymptomatic infection than those with symptomatic infection (relative risk 0.35, 95% CI 0.10-1.27). Modelling studies fit to data found a higher proportion of all SARS-CoV-2 infections resulting from transmission from pre-symptomatic individuals than from asymptomatic individuals. Limitations of the review include that most included studies were not designed to estimate the proportion of asymptomatic SARS-CoV-2 infections and were at risk of selection biases, we did not consider the possible impact of false negative RT-PCR results, which would underestimate the proportion of asymptomatic infections, and that the database does not include all sources. CONCLUSIONS The findings of this living systematic review of publications early in the pandemic suggest that most SARS-CoV-2 infections are not asymptomatic throughout the course of infection. The contribution of pre-symptomatic and asymptomatic infections to overall SARS-CoV-2 transmission means that combination prevention measures, with enhanced hand hygiene, masks, testing tracing and isolation strategies and social distancing, will continue to be needed. AUTHOR SUMMARY Why was this study done? ▪ The proportion of people who will remain asymptomatic throughout the course of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (covid-19), is not known. ▪ Studies that assess people at just one time point will overestimate the proportion of true asymptomatic infection because those who go on to develop covid-19 symptoms will be wrongly classified as asymptomatic, rather than pre-symptomatic. ▪ The amount, and infectiousness, of asymptomatic SARS-CoV-2 infection will determine what kind of measures will prevent transmission most effectively. What did the researchers do and find? ▪ We did a living systematic review through 10 June 2020, using automated workflows that speed up the review processes, and allow the review to be updated when relevant new evidence becomes available. ▪ Overall, in 79 studies in a range of different settings, 20% (95% confidence interval, CI 17–25%) of people with SARS-CoV-2 infection remained asymptomatic during follow-up, but biases in study designs limit the certainty of this estimate. ▪ We found some evidence that SARS-CoV-2 infection in contacts of people with asymptomatic infection is less likely than in contacts of people with symptomatic infection (relative risk 0.35, 95% CI 0.10-1.27). What do these findings mean? ▪ The findings of this living systematic review suggest that most SARS-CoV-2 infections are not asymptomatic throughout the course of infection. ▪ Future studies should be designed specifically to determine the true proportion of asymptomatic SARS-CoV-2 infections, using methods to minimise biases in the selection of study participants and ascertainment of symptom status during follow up. ▪ The contribution of pre-symptomatic and asymptomatic infections to overall SARS-CoV-2 trans
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C.-Y., Poon, R. W.-S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,944
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001737 · Cited by 4,810
Presumed Asymptomatic Carrier Transmission of COVID-19
Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D.-Y., Chen, L., & Wang, M. (2020) · JAMA · doi:10.1001/jama.2020.2565 · Cited by 4,498
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,247
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Research works printed but not linked: 31
- 2017, Rapid Reviews to Strengthen Health Policy and Systems: A Practical Guide
- Buitrago-Garcia D, Egli-Gany D, Counotte M, Hossmann S, Imeri H, Salanti G, et al. The Role of Asymptomatic Sars-Cov-2 Infections: Rapid Living Systematic Review and Meta-Analysis. Version 1. medRxiv [Preprint]. 2020 [cited 2020 Jul 27]. Available from: https://doi.org/10.1101/2020.04.25.20079103 · DOI
- Buitrago-Garcia D, Egli-Gany D, Counotte M, Hossmann S, Imeri H, Salanti G, et al. The Role of Asymptomatic Sars-Cov-2 Infections: Rapid Living Systematic Review and Meta-Analysis. Version 2. medRxiv [Preprint]. 2020 [cited 2020 Jul 27]. Available from: https://doi.org/10.1101/2020.04.25.20079103 · DOI
- M Counotte, 2020, Covid-19 Living Evidence. Bern: Institute of Social and Preventive Medicine
- JF Chan, 2019, Novel Coronavirus Indicating Person-to-Person Transmission: A Study of a Family Cluster, Lancet, 395, 514
- SH Luo, 2020, A Confirmed Asymptomatic Carrier of 2019 Novel Coronavirus, Chin Med J (Engl), 133, 1123, 10.1097/CM9.0000000000000798 · doi:10.1097/cm9.0000000000000798
- Tabata S, Imai K, Kawano S, Ikeda M, Kodama T, Miyoshi K, et al. Non-Severe Vs Severe Symptomatic Covid-19: 104 Cases from the Outbreak on the Cruise Ship 'Diamond Princess' in Japan. medRxiv [Preprint]. 2020 [cited 2020 Jul 27]. doi: 10.1101/2020.03.18.20038125 · DOI
- Luo L, Liu D, Liao X-l, Wu X-b, Jing Q-l, Zheng J-z, et al. Modes of Contact and Risk of Transmission in Covid-19 among Close Contacts. bioRxiv [Preprint]. 2020 [cited 2020 Jul 27]. Available from: https://www.medrxiv.org/content/10.1101/2020.03.24.20042606v1 · DOI
- KC See, 2020, Covid-19: Four Paediatric Cases in Malaysia, Int J Infect Dis, 94, 125, 10.1016/j.ijid.2020.03.049 · DOI
- Tian S, Wu M, Chang Z, Wang Y, Zhou G, Zhang W, et al. Epidemiological Investigation and Intergenerational Clinical Characteristics of 24 Covid-19 Patients Associated with Supermarket Cluster. bioRxiv [Preprint]. 2020 [cited 2020 Jul 27]. doi: 10.1101/2020.04.11.20058891 · doi:10.1101/2020.04.11.20058891
- Y Wang, 2020, Clinical Outcome of 55 Asymptomatic Cases at the Time of Hospital Admission Infected with Sars-Coronavirus-2 in Shenzhen, China, J Infect Dis
- HO Al-Shamsi, 2020, Screening for Covid-19 in Asymptomatic Patients with Cancer in a Hospital in the United Arab Emirates, JAMA Oncol
- K Bai, 2020, Clinical Analysis of 25 Novel Coronavirus Infections in Children, Pediatr Infect Dis J
- Casey M, Griffin J, McAloon CG, Byrne AW, Madden JM, McEvoy D, et al. Estimating Pre-Symptomatic Transmission of Covid-19: A Secondary Analysis Using Published Data. medRxiv [Preprint]. 2020 [cited 2020 Jul 27]. doi: 10.1101/2020.05.08.20094870 · DOI
- Chang MC, Hur J, Park D. Chest Computed Tomography Findings in Asymptomatic Patients with Covid-19. medRxiv [Preprint]. 2020 [cited 2020 Jul 27]. doi: 10.1101/2020.05.09.20096370 · doi:10.1101/2020.05.09.20096370
- Y Gao, 2020, A Cluster of the Corona Virus Disease 2019 Caused by Incubation Period Transmission in Wuxi, China, J Infect
- L Huang, 2020, Initial Ct Imaging Characters of an Imported Family Cluster of Covid-19, Clin Imaging
- R Huang, 2020, A Family Cluster of Covid-19 Involving an Asymptomatic Case with Persistently Positive Sars-Cov-2 in Anal Swabs, Travel Med Infect Dis
- XL Jiang, 2020, Transmission Potential of Asymptomatic and Paucisymptomatic Sars-Cov-2 Infections: A Three-Family Cluster Study in China, J Infect Dis
- W Kong, 2020, Comparison of Clinical and Epidemiological Characteristics of Asymptomatic and Symptomatic Sars-Cov-2 Infection: A Multi-Center Study in Sichuan Province, China, Travel Med Infect Dis
- Kumar R, Bhattacharya B, Meena VP, Aggarwal A, Tripathi M, Soneja M, et al. Management of Mild Covid-19: Policy Implications of Initial Experience in India. medRxiv [Preprint]. 2020 [cited 2020 Jul 27]. doi: 10.1101/2020.05.20.20107664 · doi:10.1101/2020.05.20.20107664
- Y Luo, 2020, Asymptomatic Sars-Cov-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China, Emerg Infect Dis
- Y Ma, 2020, Characteristics of Asymptomatic Patients with Sars-Cov-2 Infection in Jinan, China. Microbes Infect
- X Tan, 2020, Clinical Features of Children with Sars-Cov-2 Infection: An Analysis of 13 Cases from Changsha, China, Zhongguo Dang Dai Er Ke Za Zhi
- Pham TQ, Rabaa MA, Duong LH, Dang TQ, Tran QD, Quach HL, et al. The First 100 Days of Sars-Cov-2 Control in Vietnam. medRxiv [Preprint]. 2020 [cited 2020 Jul 27]. doi: 10.1101/2020.05.12.20099242 · doi:10.1101/2020.05.12.20099242
- Y Wang, 2020, Characterization of an Asymptomatic Cohort of Sars-Cov-2 Infected Individuals Outside of Wuhan, China, Clin Infect Dis
- HP Wu, 2020, Clinical Features of Coronavirus Disease 2019 in Children Aged <18 Years in Jiangxi, China: An Analysis of 23 Cases, Zhongguo Dang Dai Er Ke Za Zhi, 22, 419
- Xu H, Liu E, Xie J, Smyth R, Zhou Q, Zhao R, et al. A Follow-up Study of Children Infected with Sars-Cov-2 from Western China. medRxiv [Preprint]. 2020 [cited 2020 Jul 27]. doi: 10.1101/2020.04.20.20073288 · doi:10.1101/2020.04.20.20073288
- Zhang W, Long Q, Huang Y, Chen C, Wu J, Hong Y, et al. Asymptomatic Covid-19 Have Longer Treatment Cycle Than Moderate Type of Confirmed Patients. medRxiv [Preprint]. 2020 [cited 2020 Jul 27]. doi: 10.1101/2020.05.16.20103796 · doi:10.1101/2020.05.16.20103796
- NVV Chau, 2020, The Natural History and Transmission Potential of Asymptomatic Sars-Cov-2 Infection, Clin Infect Dis
- C Heneghan, 2020, Covid-19: What Proportion Are Asymptomatic?
Cited by
SARS-CoV-2 Transmission From People Without COVID-19 Symptoms
Johansson, M. A., Quandelacy, T. M., Kada, S., Prasad, P. V., Steele, M., Brooks, J. T., Slayton, R. B., Biggerstaff, M., & Butler, J. C. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.35057 · Cited by 1,025
Mapping the human genetic architecture of COVID-19
Initiative, C.-1. H. G., InitiativeLeadership, C.-1. H. G., Niemi, M. E. K., Karjalainen, J., Liao, R. G., Neale, B. M., Daly, M., Ganna, A., Writing group, Writing group leaders, et al. (2021) · Nature · doi:10.1038/s41586-021-03767-x · Cited by 983
Sallis, R., Young, D. R., Tartof, S. Y., Sallis, J. F., Sall, J., Li, Q., Smith, G. N., & Cohen, D. A. (2021) · British Journal of Sports Medicine · doi:10.1136/bjsports-2021-104080 · Cited by 789
Miller, S. L., Nazaroff, W. W., Jimenez, J. L., Boerstra, A., Buonanno, G., Dancer, S. J., Kurnitski, J., Marr, L. C., Morawska, L., & Noakes, C. (2021) · Indoor Air · doi:10.1111/ina.12751 · Cited by 734
Virology, transmission, and pathogenesis of SARS-CoV-2
Cevik, M., Kuppalli, K., Kindrachuk, J., & Peiris, M. (2020) · BMJ · doi:10.1136/bmj.m3862 · Cited by 732
(2020) · doi:10.3138/jammi-2020-0030 · Cited by 664
False-negative results of initial RT-PCR assays for COVID-19: A systematic review
Arevalo-Rodriguez, I., Buitrago-Garcia, D., Simancas-Racines, D., Zambrano-Achig, P., Del Campo, R., Ciapponi, A., Sued, O., Martinez-García, L., Rutjes, A. W., Low, N., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0242958 · Cited by 656
Self-citationAsymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis
Sah, P., Fitzpatrick, M. C., Zimmer, C. F., Abdollahi, E., Juden-Kelly, L., Moghadas, S. M., Singer, B. H., & Galvani, A. P. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109229118 · Cited by 488
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study
Marks, M., Millat-Martinez, P., Ouchi, D., Roberts, C. H., Alemany, A., Corbacho-Monné, M., Ubals, M., Tobias, A., Tebé, C., Ballana, E., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30985-3 · Cited by 347
Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review
van Kessel, S. A. M., Olde Hartman, T. C., Lucassen, P. L. B. J., & van Jaarsveld, C. H. M. (2022) · Family Practice · doi:10.1093/fampra/cmab076 · Cited by 345
Datta, S. D., Talwar, A., & Lee, J. T. (2020) · JAMA · doi:10.1001/jama.2020.22717 · Cited by 316
FALSE-NEGATIVE RESULTS OF INITIAL RT-PCR ASSAYS FOR COVID-19: A SYSTEMATIC REVIEW
Arevalo-Rodriguez, I., Buitrago-Garcia, D., Simancas-Racines, D., Zambrano-Achig, P., Campo, R. D., Ciapponi, A., Sued, O., Martínez-García, L., Rutjes, A., Low, N., et al. (2020) · medRxiv · doi:10.1101/2020.04.16.20066787 · Cited by 310
Self-citationRahman, S., Montero, M. T. V., Rowe, K., Kirton, R., & Kunik, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1902303 · Cited by 289
Modeling transmission of SARS-CoV-2 Omicron in China
Cai, J., Deng, X., Yang, J., Sun, K., Liu, H., Chen, Z., Peng, C., Chen, X., Wu, Q., Zou, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01855-7 · Cited by 281
COVID-19: A review of therapeutic strategies and vaccine candidates
Izda, V., Jeffries, M. A., & Sawalha, A. H. (2021) · Clinical Immunology · doi:10.1016/j.clim.2020.108634 · Cited by 274
Fontanet, A., Tondeur, L., Grant, R., Temmam, S., Madec, Y., Bigot, T., Grzelak, L., Cailleau, I., Besombes, C., Ungeheuer, M.-N., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.15.2001695 · Cited by 264
Underdetection of cases of COVID-19 in France threatens epidemic control
Pullano, G., Di Domenico, L., Sabbatini, C. E., Valdano, E., Turbelin, C., Debin, M., Guerrisi, C., Kengne-Kuetche, C., Souty, C., Hanslik, T., et al. (2021) · Nature · doi:10.1038/s41586-020-03095-6 · Cited by 253
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
Bobrovitz, N., Arora, R. K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., Chen, J., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252617 · Cited by 246
CT of Post-Acute Lung Complications of COVID-19
Solomon, J. J., Heyman, B., Ko, J. P., Condos, R., & Lynch, D. A. (2021) · Radiology · doi:10.1148/radiol.2021211396 · Cited by 212
Cohen, C., Kleynhans, J., Gottberg, A. V., McMorrow, M. L., Wolter, N., Bhiman, J. N., Moyes, J., Plessis, M. D., Carrim, M., Buys, A., et al. (2021) · doi:10.1101/2021.07.20.21260855 · Cited by 153
Qiu, X., Nergiz, A. I., Maraolo, A. E., Bogoch, I. I., Low, N., & Cevik, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.01.011 · Cited by 135
Self-citationThe timing of COVID-19 transmission
Ferretti, L., Ledda, A., Wymant, C., Zhao, L., Ledda, V., Abeler-Dörner, L., Kendall, M., Nurtay, A., Cheng, H.-Y., Ng, T.-C., et al. (2020) · doi:10.1101/2020.09.04.20188516 · Cited by 112
Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines
Lewnard, J. A., Patel, M. M., Jewell, N. P., Verani, J. R., Kobayashi, M., Tenforde, M. W., Dean, N. E., Cowling, B. J., & Lopman, B. A. (2021) · Epidemiology · doi:10.1097/ede.0000000000001366 · Cited by 103
Masks and Face Coverings for the Lay Public: A Narrative Update
Czypionka, T., Greenhalgh, T., Bassler, D., & Bryant, M. B. (2021) · Annals of Internal Medicine · doi:10.7326/m20-6625 · Cited by 82
(2022) · doi:10.1371/journal.pmed.1003987 · Cited by 81
Kahn, R., Schrag, S. J., Verani, J. R., & Lipsitch, M. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac015 · Cited by 76
Increased infections, but not viral burden, with a new SARS-CoV-2 variant
Walker, A. S., Vihta, K.-D., Gethings, O., Pritchard, E., Jones, J., House, T., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., et al. (2021) · doi:10.1101/2021.01.13.21249721 · Cited by 58
Quattrocchi, A., Mamais, I., Tsioutis, C., Christaki, E., Constantinou, C., Koliou, M., Pana, Z.-D., Silvestros, V., Theophanous, F., Haralambous, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113598 · Cited by 28
How to update a living systematic review and keep it alive during a pandemic: a practical guide
Heron, L., Buitrago-Garcia, D., Ipekci, A. M., Baumann, R., Imeri, H., Salanti, G., Counotte, M. J., & Low, N. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02325-y · Cited by 26
“In our case study (Table 2), we have published both preprints [24, 47] and peer-reviewed articles [10, 48].”
Self-citation(2022) · doi:10.1101/2022.01.20.22269581 · Cited by 13
Mugenyi, L., Nsubuga, R. N., Wanyana, I., Muttamba, W., Tumwesigye, N. M., & Nsubuga, S. H. (2021) · PLOS ONE · doi:10.1371/journal.pone.0260269 · Cited by 11
Morgenstern, C., Rawson, T., Routledge, I., Kont, M., Imai-Eaton, N., Skarp, J., Doohan, P., McCain, K., Johnson, R., Unwin, H. J. T., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2025.101144 · Cited by 6
How to update a living systematic review and keep it alive during a pandemic: a practical guide
(2023) · doi:10.21203/rs.3.rs-2364994/v1
Metadata
- Authors
- Buitrago-Garcia, D., Egli-Gany, D., Counotte, M. J., Hossmann, S., Imeri, H., Ipekci, A. M., Salanti, G., & Low, N.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-09-22
- Volume
- 17
- Issue
- 9
- Pages
- e1003346
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W3087248341
- Cited by
- 1,000
- References
- 111
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_176233)
- European Union Horizon 2020 research and innovation programme (101003688)
- Swiss Government Excellence Scholarship (2019.0774)
- Swiss School of Public Health plus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.